C4X Discovery Holdings PLC Sanofi Agreement (0457V)
April 12 2021 - 2:00AM
UK Regulatory
TIDMC4XD
RNS Number : 0457V
C4X Discovery Holdings PLC
12 April 2021
C4X Discovery Holdings plc
Up to EUR414 million Exclusive Worldwide Licensing Agreement
with Sanofi for C4XD oral IL-17A inhibitor programme
EUR7 million upfront payment in addition to potential
pre-clinical milestones of EUR11 million,
clinical and commercial milestones plus royalties
Second major licensing deal with a global pharmaceutical company
in commercially attractive markets
12 April 2021 - C4X Discovery Holdings plc (AIM: C4XD), a
pioneering Drug Discovery company, today announces that its
subsidiary, C4X Discovery Limited ("C4XD", "C4X Discovery" or the
"Company"), has signed an exclusive worldwide licensing agreement
with Sanofi (NASD: SNY, PAR: SAN - "Sanofi "), worth up to EUR414
million, for C4XD's oral pre-clinical IL-17A inhibitor programme.
Under the terms of the agreement, C4XD will receive an upfront
payment of EUR7 million and could receive up to a further EUR407
million in potential development, regulatory and commercialisation
milestones, of which EUR11 million is in pre-clinical milestones,
in addition to single digit royalties.
Under the license, Sanofi will develop and commercialise an oral
therapy for the treatment of inflammatory diseases, a multi-billion
dollar market. The IL-17 family of cytokines are strong inducers of
inflammation and are implicated in a variety of autoimmune diseases
including psoriasis, psoriatic arthritis and ankylosing
spondylitis. Current treatments targeting IL-17 are monoclonal
antibodies administered via an injection. There is an urgent need
for safe and efficacious oral small molecule therapies to increase
the number of patients able to access IL-17 targeted drugs and
expand availability into new inflammatory disease indications.
C4XD's small molecule IL-17A inhibitor programme can selectively
block IL-17 activity in vivo whilst maintaining molecular size of
the molecule in the traditional "drug-like" range suitable for oral
administration. Sanofi will continue to work with the C4XD team to
access its unique and proprietary 4D Conformetrix technology, as
the programme advances towards clinical studies.
Clive Dix, CEO of C4X Discovery, said: "We are proud to be
working with Sanofi to create much needed oral therapies in the
underserved inflammatory disease space. While antibody therapies
have demonstrated the potential of IL-17 inhibition in the
generation of highly effective treatments, the injectable route
means many patients currently do not have access to the medicines
that can change their lives. We believe that our small molecule
programme has the potential to create high value, efficacious and
convenient oral IL-17 therapeutics for this large market. The
Psoriasis market alone is estimated to be worth c.$24 billion per
annum by 2027(1) , and when combined with Sanofi's development
expertise our programme has the potential to address a number of
indications.
"This is the second significant agreement for a C4XD programme
and marks a major milestone for the Company, not only validating
the strength of our Drug Discovery expertise, but also our strategy
to drive shareholder value through early-stage revenue generating
deals. With Indivior progressing our molecule for opioid addiction
through a Phase I clinical trial and now our partnership with
Sanofi driving potential next generation oral IL-17 therapies, we
look forward with confidence to further develop our portfolio and
deliver additional novel small molecule drug candidates tackling
significant patient needs."
1. Plaque Psoriasis: Global Drug Forecast and Market Analysis to
2027, GlobalData, December 2018
- Ends -
Contacts
C4X Discovery Holdings
Mo Noonan, Communications +44 (0)787 6444977
Panmure Gordon (UK) Limited (NOMAD and
Broker)
Freddy Crossley, Emma Earl (Corporate
Finance) +44 (0)20 7886 2500
Rupert Dearden (Corporate Broking)
C4X Discovery Media - Consilium Strategic
Communications
Mary-Jane Elliott, Chris Gardner, Matthew
Neal +44 (0)203 709 5700
Notes to Editors:
About C4X Discovery
C4X Discovery ("C4XD") is a pioneering Drug Discovery company
combining scientific expertise with cutting-edge Drug Discovery
technologies to efficiently deliver world--leading medicines, which
are developed by our partners for the benefit of patients. We have
a highly valuable and differentiated approach to Drug Discovery
through our enhanced DNA-based target identification and candidate
molecule design capabilities, generating small molecule drug
candidates across multiple disease areas including inflammation,
neurodegeneration, oncology and addictive disorders . Our
commercially attractive portfolio ranges from early stage novel
target opportunities to late stage Drug Discovery programmes ready
for out-licensing to partners and we have two commercially
partnered programmes with one candidate in clinical
development.
We collaborate with leading pharmaceutical and life sciences
companies to enrich our expertise and take our assets through
pre-clinical and clinical development. Through early-stage
revenue-generating licensing deals, we realise returns from our
high value pre-clinical assets which are reinvested to maximise the
value of our Drug Discovery portfolio. For more information visit
us at www.c4xdiscovery.com or follow us on twitter @C4XDiscovery
.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014 (MAR).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGREAKLNEFSFEFA
(END) Dow Jones Newswires
April 12, 2021 02:00 ET (06:00 GMT)
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Sep 2024 to Oct 2024
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Oct 2023 to Oct 2024